Elpis Biopharmaceuticals is focused on advancing cancer treatment through innovative technologies, particularly in the realm of cell therapy. Their mRNADis™ platform facilitates the rapid screening and discovery of highly selective and potent single-chain variable fragment (ScFv) or variable heavy (VH) domain antibody modules. This technology allows for the selection of antibodies against therapeutic targets using both soluble proteins and live cells, which is crucial for identifying antibodies that bind to disease-relevant epitopes, including challenging targets like multi-transmembrane proteins. Additionally, the ScFv and VH domains can be engineered to create bispecific or multifunctional modalities, enhancing their therapeutic potential.

Another key technology employed by Elpis is mSCAFold™, which involves the rational design of tailored libraries based on the structural and functional relationships between targets and their interaction partners. This platform utilizes mRNA display technology to screen and identify engineered mutants with modified pharmacological properties, such as agonists or antagonists, for therapeutic applications. The advantages of these discovery platforms include the generation of fully human antibody libraries with a vast diversity, lower immunogenicity, and the ability to create donor or disease-specific libraries. Furthermore, live cell selections enable the identification of lead molecules that recognize native conformations of desired epitopes, ultimately leading to the development of more efficacious and safer therapeutic candidates.

United States

Elpis Biopharmaceuticals is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company has a strong leadership team and has received significant funding to support its research and development efforts.

Elpis Biopharmaceuticals

Company Details